Welcome to our dedicated page for Generation Bio news (Ticker: GBIO), a resource for investors and traders seeking the latest updates and insights on Generation Bio stock.
Generation Bio Co. has reported biotechnology and corporate-status developments tied to its historical focus on genetic-medicine approaches for T cell-driven autoimmune diseases. Company updates have covered the ctLNP cell-targeted lipid nanoparticle delivery system, siRNA delivery to T cells, operating and financial results, stock and listing-related actions, equity awards, and leadership transitions.
Later public disclosures also place GBIO in a corporate transition context, with strategic-alternatives language followed by regulatory records addressing delisting and Exchange Act deregistration notices for its common stock.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Generation Bio (Nasdaq:GBIO) has announced that CEO Geoff McDonough, M.D., will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18th at 3:00 p.m. EST. Investors can access a live webcast on the company's investor website, with a replay available for 30 days after the event.
Generation Bio specializes in genetic medicines aimed at providing sustainable, redosable treatments for both rare and common diseases. Their innovative platform utilizes a unique non-viral genetic medicine, featuring closed-ended DNA (ceDNA) and a specialized delivery system known as cell-targeted lipid nanoparticles (ctLNP). This technology is designed to enable long-lasting treatment effects from a single dose and has the potential to significantly scale up production.
Generation Bio Co. (Nasdaq:GBIO) has appointed Yalonda Howze, J.D., as its chief legal officer and secretary. Howze brings nearly two decades of legal experience in biotechnology and life sciences, having previously served at Codiak BioSciences and as a partner at Mintz Levin. CEO Geoff McDonough expressed optimism about her contributions to the company’s ambitious goal of developing transformative genetic medicines for rare and prevalent diseases. Generation Bio focuses on innovative genetic therapies using its proprietary non-viral delivery system, aiming for long-lasting and adjustable treatments.